- Home
- EVGO vs IMMP Comparison
EVGO vs IMMP Comparison
Compare EVGO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGO
- IMMP
- Stock Information
- Founded
- EVGO 2010
- IMMP 1987
- Country
- EVGO United States
- IMMP Australia
- Employees
- EVGO N/A
- IMMP N/A
- Industry
- EVGO Other Specialty Stores
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- EVGO Consumer Discretionary
- IMMP Health Care
- Exchange
- EVGO Nasdaq
- IMMP Nasdaq
- Market Cap
- EVGO 376.5M
- IMMP 211.1M
- IPO Year
- EVGO N/A
- IMMP N/A
- Fundamental
- Price
- EVGO $3.83
- IMMP $1.86
- Analyst Decision
- EVGO Strong Buy
- IMMP Buy
- Analyst Count
- EVGO 10
- IMMP 2
- Target Price
- EVGO $5.78
- IMMP $8.50
- AVG Volume (30 Days)
- EVGO 3.9M
- IMMP 648.0K
- Earning Date
- EVGO 05-06-2025
- IMMP 05-16-2025
- Dividend Yield
- EVGO N/A
- IMMP N/A
- EPS Growth
- EVGO N/A
- IMMP N/A
- EPS
- EVGO N/A
- IMMP N/A
- Revenue
- EVGO $276,954,000.00
- IMMP $3,019,249.00
- Revenue This Year
- EVGO $39.82
- IMMP $11.25
- Revenue Next Year
- EVGO $32.12
- IMMP $10.22
- P/E Ratio
- EVGO N/A
- IMMP N/A
- Revenue Growth
- EVGO 45.15
- IMMP 24.11
- 52 Week Low
- EVGO $1.78
- IMMP $1.32
- 52 Week High
- EVGO $9.07
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- EVGO 79.08
- IMMP 53.43
- Support Level
- EVGO $2.66
- IMMP $1.44
- Resistance Level
- EVGO $4.17
- IMMP $2.71
- Average True Range (ATR)
- EVGO 0.23
- IMMP 0.17
- MACD
- EVGO 0.13
- IMMP 0.05
- Stochastic Oscillator
- EVGO 81.13
- IMMP 29.75
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.